ETH Zurich publishes research on new AI drug discovery model

27 November 2023
ai_drug_discovery_big

A new artificial intelligence (AI)-based model developed by scientists at ETH Zurich could help determine optimal synthesis methods for new active pharmaceutical ingredients (API).

Published in  Nature Chemistry, the work promises to help scientists avoid a trial-​and-error approach, whereby chemical reactions are tested sequentially in a way which can be highly time consuming.

Working with the research and early development unit of Swiss cancer giant Roche (ROG: SIX), ETH Zurich has developed the model to help predict where a pharmaceutically active molecule can be chemically modified.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical